menu ☰
menu ˟

[Correspondence] Questions regarding the CONCERN trial

13 Jan 2018

Findings from Francis Chan and colleagues' study (June 17, 2017, p 2375)1 showed a 6·7% absolute risk reduction in recurrent upper gastrointestinal bleeding with celecoxib plus esomeprazole compared with naproxen and esomeprazole in patients who were on non-steroidal anti-inflammatory drugs and receiving concomitant aspirin following an upper gastrointestinal bleed. Additionally, the authors reported no significant difference between groups in serious cardiovascular events (4·4% [95% CI 2·4–7·7] for patients given celecoxib plus esomeprazole vs 5·5% [3·3–9·2] for those given naproxen plus esomeprazole; p=0·543), although their study was not adequately powered to evaluate this secondary outcome.

Click here to view the full article which appeared in The Lancet